November is Lung Cancer Awareness Month, and what better way is there to spend your time than getting to know the recent advances in adjuvant therapy for early-stage lung adenocarcinoma? 

Learning Objectives

-        Review work-up and treatment of lung adenocarcinoma
-        Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
-        Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
-        Discuss future directions for research
-        Discuss additional advancements in diagnosis, monitoring, and immunotherapy

Referenced Material

-        Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071  https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
-        Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
-        Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext

Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.